[
  {
    "ts": null,
    "headline": "Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer",
    "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera’s innovative molecular glue degrader/MGD […]",
    "url": "https://finnhub.io/api/news?id=6aab5514dc5881a308f52cd4da7bc3ffdb1ab50a4d51ba1b4fec72c549cdb6a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751098568,
      "headline": "Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer",
      "id": 135610060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera’s innovative molecular glue degrader/MGD […]",
      "url": "https://finnhub.io/api/news?id=6aab5514dc5881a308f52cd4da7bc3ffdb1ab50a4d51ba1b4fec72c549cdb6a8"
    }
  }
]